A single-arm, phase II study of neoadjuvant MPDL3280A, nab-paclitaxel and carboplatin (MAC) in resectable non-small cell lung cancer (NSCLC)
A study for patients with non-small cell lung cancer (NSCLC) using study drug atezolizumab with standard chemotherapy to shrink tumors
Sponsor: Genentech, Inc., Celgene Corporation
Enrolling: Male and Female Patients
IRB Number: AAAQ3153
U.S. Govt. ID: NCT02716038
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is for patients who are being considered for surgical removal of a specific kind of lung cancer called "non-small lung cancer" (NSCLC), which is a description of the way it looks under a microscope. The purpose of this study is to determine whether adding an investigational treatment called atezolizumab (also called MPDL3280A) to standard chemotherapy before surgery will result in additional shrinking of the cancer.
This study is closed
Catherine Shu, MD
Do You Qualify?
Have you been diagnosed with Non-Small-Cell Lung Cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator